Last $3.79 USD
Change Today -0.05 / -1.30%
Volume 1.5M
ARRY On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

array biopharma inc (ARRY) Snapshot

Open
$3.85
Previous Close
$3.84
Day High
$3.92
Day Low
$3.73
52 Week High
08/2/13 - $7.10
52 Week Low
04/15/14 - $3.39
Market Cap
475.5M
Average Volume 10 Days
2.0M
EPS TTM
$-0.54
Shares Outstanding
125.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ARRAY BIOPHARMA INC (ARRY)

array biopharma inc (ARRY) Related Bloomberg News

View More Bloomberg News

array biopharma inc (ARRY) Related Businessweek News

No Related Businessweek News Found

array biopharma inc (ARRY) Details

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases primarily in North America, Europe, and the Asia Pacific. Its proprietary clinical programs include ARRY-520, a kinesin spindle protein inhibitor, which is in Phase 2 clinical trial for patients with multiple myeloma; ARRY-614, a p38/Tie2 dual inhibitor that is in Phase 1 clinical trial for the treatment of myelodysplastic syndromes; ARRY-797, a p38 inhibitor, which is in Phase 2 clinical trial for pain; and ARRY-502, a CRTh2 antagonist that is in Phase 2 clinical trial for asthma. The company’s partnered clinical programs comprise drug candidates for the treatment of cancer, including MEK162, an MEK inhibitor in Phase 3 clinical trial; Selumetinib, an MEK inhibitor in Phase 2/pivotal clinical trial; and GDC-0068 AKT inhibitor, LY2606368 Chk-1 inhibitor, and VTX-2337 toll-like receptor in Phase 2 clinical trial. Its partnered clinical programs also include Danoprevir, a Hepatitis C virus protease inhibitor in Phase 2 clinical trial; ARRY-543/ASLAN001, a HER2/EGFR inhibitor for gastric cancer in Phase 2 clinical trial; GDC-0575 and GDC-0425 Chk-1 inhibitors for cancer in Phase 1b clinical trial; ARRY-380, an HER2 inhibitor in Phase 1 clinical trial for breast cancer; and GDC-0994 in a Phase 1 dose-escalation study in patients with locally advanced or metastatic solid tumors. The company has collaborations with Amgen Inc.; ASLAN Pharmaceuticals Pte Ltd.; AstraZeneca, PLC; Celgene Corporation; Eli Lilly and Company; Genentech Inc.; Novartis International Pharmaceutical Ltd.; Oncothyreon Inc.; and VentiRx Pharmaceuticals, Inc. for the development and commercialization of the partnered drugs. Array BioPharma Inc. was founded in 1998 and is headquartered in Boulder, Colorado.

265 Employees
Last Reported Date: 08/12/13
Founded in 1998

array biopharma inc (ARRY) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $528.2K
Co-Founder, Chief Operating Officer and Vice ...
Total Annual Compensation: $384.3K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $348.9K
Vice President, General Counsel and Secretary
Total Annual Compensation: $357.5K
Chief Medical Officer
Total Annual Compensation: $175.0K
Compensation as of Fiscal Year 2013.

array biopharma inc (ARRY) Key Developments

Array BioPharma Provides Clinical Update on ARRY-502 for Asthma at Scientific Meeting

Array BioPharma Inc. reported full results from a randomized Phase 2 trial of ARRY-502 in patients with mild to moderate Th2-Driven Asthma at the 2014 American Academy Of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. ARRY-502, an oral CRTh2 antagonist, was studied in a 184-patient placebo-controlled, randomized, double--blind Phase 2 trial in mild to moderate persistent allergic asthma, a population representing more than 12 million patients in the U.S. ARRY-502 met the primary endpoint in the trial, showing improved pre-bronchodilator Forced Expiratory Volume in one second (FEV1), a measure of lung function, by 3.9% versus placebo, achieving statistical significance (p=0.02). FEV1 responses for the total cohort were statistically significant on a week by week basis. A predefined endpoint using the median baseline value of FENO (fractional exhaled nitric oxide), a Th2 associated biomarker, was also evaluated. FENO measurement is an office-based, noninvasive method for evaluating pulmonary inflammation. Patients with elevated baseline FENO demonstrated enhanced activity with a median FEV1 improvement of 6.8% relative to placebo at week 4 (p=0.008). This is the first published report demonstrating that CRTh2 antagonism provides meaningful clinical benefit specifically in patients with high FENO. Overall, ARRY-502 was well tolerated, with fewer adverse events in the ARRY-502 group as compared to the placebo group, including fewer asthma exacerbations (ARRY-502, n=4; placebo, n=9). There were no treatment-emergent serious adverse events in patients receiving ARRY-502 and all treatment-related adverse events were mild or moderate in severity. In addition, there were no significant changes observed in the safety signals QTc, hematology or vital signs in patients treated with ARRY-502. A total of 15 out of 184 patients discontinued the study early with fewer discontinuations occurring on the ARRY-502 arm (ARRY-502, n=4; placebo, n=11). Six of these discontinuations were due to asthma exacerbations (ARRY-502, n=1; placebo, n=5).

Oncothyreon Inc. and Array Biopharma Inc. Announce Initiation of Phase 1b Trial of ONT-380 in Combination with TDM-1 in Patients with Metastatic HER2+ Breast Cancer

Oncothyreon Inc. and Array BioPharma Inc. announced the initiation of a Phase 1b trial of ONT-380 (ARRY-380) in combination with Kadcyla(R) (ado-trastuzumab emtansine or TDM-1) in patients with metastatic HER2+ breast cancer. ONT-380 is an orally active, reversible and selective small-molecule HER2 inhibitor invented by Array and being developed by Oncothyreon in collaboration with Array. The trial is a dose-escalation study in up to 48 patients who have been previously treated with Herceptin(R) (trastuzumab) and a taxane for metastatic breast cancer. The primary objective is to determine the maximum-tolerated and/or recommended Phase 2 dose (MTD/RP2D) of ONT-380 in combination with the approved dose of Kadcyla. Secondary objectives include an evaluation of the safety and preliminary anti-tumor activity of the combination. Following determination of the MTD/RP2D, the study includes an expansion arm at the MTD/RP2D as well as an optional second expansion arm in patients with central nervous system metastases. ONT-380 is an orally active, reversible and selective HER2 inhibitor. In multiple preclinical tumor models, ONT-380 was well tolerated and demonstrated significant dose-related tumor growth inhibition that was superior to Herceptin and Tykerb(R) (lapatinib). A Phase 1 trial of ONT-380, with both dose-escalation and expansion components, has been completed in 50 patients, 43 of whom had HER2+ metastatic breast cancer. All HER2+ breast cancer patients had progressed on a Herceptin-containing regimen. In addition, over 80% had been treated with Tykerb, with many having progressed on therapy. In this study, ONT-380 demonstrated an acceptable safety profile; treatment-related adverse events were primarily Grade 1. Because ONT-380 is selective for HER2 and does not inhibit EGFR, there was a low incidence and severity of treatment-related diarrhea, rash and fatigue. Twenty-two HER2+ breast cancer patients with measurable disease were treated with ONT-380 at doses greater than or equal to 600 mg BID. Notably, two of the patients with partial responses during treatment with ONT-380 had confirmed progressions while on prior Tykerb- and Herceptin-containing regimens. In addition to the Phase 1b trial of ONT-380 in combination with Kadcyla, Oncothyreon recently initiated a second Phase 1b trial of ONT-380 in combination with Herceptin and/or Xeloda(R) (capecitabine) in patients with metastatic HER2+ breast cancer. The Dana-Farber Cancer Institute, Boston, Massachusetts, is also currently conducting an investigator-sponsored trial of ONT-380 in combination with Herceptin in patients with brain metastases from HER2+ breast cancer.

Array BioPharma, Inc. Presents at RBC Capital Markets 2014 Global Healthcare Conference, Feb-25-2014 10:30 AM

Array BioPharma, Inc. Presents at RBC Capital Markets 2014 Global Healthcare Conference, Feb-25-2014 10:30 AM. Venue: New York Palace Hotel, New York, New York, United States. Speakers: Ron Squarer, Chief Executive Officer and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARRY:US $3.79 USD -0.05

ARRY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cell Therapeutics Inc $3.07 USD +0.08
Cytokinetics Inc $9.52 USD +0.45
Evotec AG €3.50 EUR -0.074
Exelixis Inc $3.29 USD -0.03
Wyeth Ltd 844.85 INR -0.15
View Industry Companies
 

Industry Analysis

ARRY

Industry Average

Valuation ARRY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.4x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.0x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARRAY BIOPHARMA INC, please visit www.arraybiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.